SELLERSVILLE, Pennsylvania (WPVI) -- A nagging cough or congestion might not mean much to most of us. But it can be serious for those with lung conditions. Exercise testing can help specialists find ...

Please provide your email address to receive an email when new articles are posted on . Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers ...

(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre® Lung in clinical trial settings.

Guardant Health is joining in on the American Lung Association’s (ALA’s) push to raise awareness about lung cancer screening and biomarker testing. The U.S. Preventive Services Task Force recommends ...

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE - An 8-year-old student blows into a spirometer held by a nurse outside an elementary school in Bel Nor, Mo., in May 2009.

Biodesix, Inc. has announced that new research will be showcased at upcoming conferences, including the ISPOR 2025 Annual Meeting in Montreal and the ATS 2025 International Conference in San Francisco ...

A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a statement issued Friday. The biotechnology company reported revenue of $6.